Do I need a prescription for Procaine hydrochloride 40mg/2ml solution for injection ampoules?

Procaine hydrochloride 40mg/2ml solution for injection ampoules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Procaine hydrochloride 40mg/2ml solution for injection ampoules?

Procaine hydrochloride 40mg/2ml solution for injection ampoules is the generic name. It is available under brand names including: Procaine hydrochloride 40mg/2ml solution for injection ampoules, Procaine hydrochloride 40mg/2ml solution for injection ampoules, Procaine hydrochloride 40mg/2ml solution for injection ampoules. (Source: NHS dm+d — Actual Medicinal Products)

Procaine hydrochloride 40mg/2ml solution for injection ampoules

Injection

40mg/2ml

Parenteral

Oral liquids

A local anesthetic of the ester type that has a slow onset and a short duration of action.

Active ingredients:

Procaine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 15.02.01

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N01BA02

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Procaine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Procaine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Procaine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

3 branded products available

3 productsShow details

3 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Procaine on the MHRA register

Procaine hydrochloride 40mg/2ml solution for injection ampoules

A A H Pharmaceuticals Ltd

Discontinued

Procaine hydrochloride 40mg/2ml solution for injection ampoules

Martindale Pharmaceuticals Ltd

Discontinued

Procaine hydrochloride 40mg/2ml solution for injection ampoules

Alliance Healthcare (Distribution) Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

9 similarShow details

Chloroprocaine 400mg/20ml solution for injection vials

Injection

400mg/20ml

Same therapeutic group

Procaine hydrochloride 500mg/500ml solution for infusion bottles

Infusion

500mg/500ml

Same therapeutic group

Chloroprocaine 50mg/5ml solution for injection ampoules

Injection

50mg/5ml

Same therapeutic group

Tetracaine 4% gel

Gel

Same therapeutic group

Ropivacaine 400mg/200ml solution for injection polyethylene bottles

Injection

400mg/200ml

Same BNF section

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Procaine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(3)

Type 1 diabetes in adults: diagnosis and management (NG17)

NG17

NICE guideline

Updated Aug 2022

Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

HTG348

Guidance

Updated Aug 2014

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

NG18

NICE guideline

Updated May 2023

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Procaine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

4957611000001102

dm+d ID

4957611000001102

VTM (Virtual Therapeutic Moiety)

777319004

VMP (Virtual Medicinal Product)

4957611000001102

BNF code

15020100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N01BA02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

140 found

Half-life

7.7 minutes

Mechanism

Procaine acts mainly by inhibiting sodium influx through voltage gated sodium ch…

Food interactions

None known

Human targets

11 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Half-life

7.7 minutes

7.7 minutes

Metabolism

Hydrolysis by plasma esterases to PABA

Elimination

With normal kidney function, the drug is excreted rapidly by tubular excretion.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Vet approved

Small molecule

About this compound

A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].

Properties:

solid

Avg. mass: 236.31 Da

DrugBank indication

Used as a local anesthetic primarily in oral surgery

Also known as(166)

2-Diethylaminoethyl p-aminobenzoate

4-aminobenzoic acid 2-diethylaminoethyl ester

Novocaine

p-Aminobenzoic acid 2-diethylaminoethyl ester

Procaina

Procaine

Procainum

Vitamin H3

Dosage forms(31)

Injection (Other)

Injection (Other) — 16 mmol/20ml

Injection, solution, concentrate (Intravenous)

Solution (Parenteral) — 0.100 g

Solution (Other) — 20.00 mg

Solution (Dental)

Injection, solution (Interstitial) — 1 %

Injection, solution (Interstitial) — 2 %

Molecular properties(18)

Drug interactions(2360)

Known interactions with other medications. Always consult a healthcare professional.

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Procaine.

Check this interaction

Dronabinol

Moderate

DB00470

Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Procaine.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Procaine.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Procaine.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Procaine can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Procaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Procaine may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Procaine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Procaine.

Check this interaction

Orphenadrine

Moderate

DB01173

Procaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Procaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Procaine.

Check this interaction

Pramipexole

Moderate

DB00413

Procaine may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Procaine may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Procaine may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Procaine.

Check this interaction

Sodium oxybate

Unknown severity

DB09072

The risk or severity of CNS depression can be increased when Procaine is combined with Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Procaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Thalidomide

Moderate

DB01041

Procaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Procaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Secretin porcine

Moderate

DB09527

The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Procaine.

Check this interaction

Prilocaine

Unknown severity

DB00750

The risk or severity of methemoglobinemia can be increased when Procaine is combined with Prilocaine.

Check this interaction

Hyaluronidase (ovine)

Moderate

DB00070

Hyaluronidase (ovine) can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects.

Check this interaction

Hyaluronidase (human recombinant)

Moderate

DB06205

Hyaluronidase (human recombinant) can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects.

Check this interaction

Hyaluronidase

Moderate

DB14740

Hyaluronidase can cause an increase in the absorption of Procaine resulting in an increased serum concentration and potentially a worsening of adverse effects.

Check this interaction

Memantine

Unknown severity

DB01043

The risk or severity of adverse effects can be increased when Procaine is combined with Memantine.

Check this interaction

Dipyridamole

Moderate

DB00975

The therapeutic efficacy of Procaine can be decreased when used in combination with Dipyridamole.

Check this interaction

Irinotecan

Unknown severity

DB00762

The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Procaine.

Check this interaction

Ephedrine

Moderate

DB01364

Procaine may increase the neuromuscular blocking activities of Ephedrine.

Check this interaction

Sar9, Met (O2)11-Substance P

Moderate

DB05875

Procaine may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.

Check this interaction

Mirabegron

Moderate

DB08893

Procaine may increase the neuromuscular blocking activities of Mirabegron.

Check this interaction

Moxisylyte

Moderate

DB09205

Procaine may increase the neuromuscular blocking activities of Moxisylyte.

Check this interaction

Propacetamol

Moderate

DB09288

Procaine may increase the neuromuscular blocking activities of Propacetamol.

Check this interaction

Pegvisomant

Moderate

DB00082

Pegvisomant may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Mefloquine

Unknown severity

DB00358

The risk or severity of methemoglobinemia can be increased when Mefloquine is combined with Procaine.

Check this interaction

Tacrine

Moderate

DB00382

Tacrine may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Sulpiride

Moderate

DB00391

Sulpiride may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Profenamine

Moderate

DB00392

Profenamine may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Gallamine triethiodide

Moderate

DB00483

Gallamine triethiodide may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Cisplatin

Unknown severity

DB00515

The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Procaine.

Check this interaction

Cinchocaine

Unknown severity

DB00527

The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Procaine.

Check this interaction

Pyridostigmine

Moderate

DB00545

Pyridostigmine may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Nizatidine

Moderate

DB00585

Nizatidine may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Galantamine

Moderate

DB00674

Galantamine may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Isoflurophate

Moderate

DB00677

Isoflurophate may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Diethylcarbamazine

Moderate

DB00711

Diethylcarbamazine may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Cocaine

Unknown severity

DB00907

The risk or severity of methemoglobinemia can be increased when Procaine is combined with Cocaine.

Check this interaction

Hexafluronium

Moderate

DB00941

Hexafluronium may increase the neuromuscular blocking activities of Procaine.

Check this interaction

Trimethaphan

Moderate

DB01116

Procaine may increase the neuromuscular blocking activities of Trimethaphan.

Check this interaction

Doxacurium

Moderate

DB01135

Procaine may increase the neuromuscular blocking activities of Doxacurium.

Check this interaction

Showing 50 of 2360 interactions

How it works

Mechanism of action

Procaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. Procaine has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.

Pharmacodynamics

Procaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Procaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Procaine is an ester anesthetic. It is metabolized in the plasma by the enzyme pseudocholinesterase through hydrolysis into para-aminobenzoic acid (PABA), which is then excreted by the kidneys into the urine.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Half-life

7.7 minutes

Metabolism

Hydrolysis by plasma esterases to PABA

Route of elimination

With normal kidney function, the drug is excreted rapidly by tubular excretion.

Drug targets(11)

Proteins and enzymes this drug interacts with in the body

Sodium channel protein type 10 subunit alpha

BE0000177

SCN10A

inhibitor

Specific functiontransmembrane transporter binding

Cellular location

Cell membrane

General function & pharmacology

Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms

Glutamate receptor ionotropic, NMDA 3A

BE0000641

GRIN3A

antagonist

Specific functioncalcium channel activity

Cellular location

Cell membrane

General function & pharmacology

Component of a non-conventional N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with low calcium permeability and low voltage-dependent block by Mg(2+) (By similarity). During the development of neural circuits, participates in the synaptic refinement period, restricting spine maturation and growth (By similarity). Forms glutamatergic receptor complexes with GluN1 and GluN2 subunits which are activated by glycine binding to the GluN1 and GluN3 subunits and L-glutamate binding to GluN2 subunits (By similarity).

Forms excitatory glycinergic receptor complexes with GluN1 alone which are activated by glycine binding to the GluN1 and GluN3 subunits .
PMID:38598639
GluN3A subunit also binds D-serine (By similarity). Each GluN3 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators (By similarity). By competing with GIT1 interaction with ARHGEF7/beta-PIX, may reduce GIT1/ARHGEF7-regulated local activation of RAC1, hence affecting signaling and limiting the maturation and growth of inactive synapses (By similarity)

5-hydroxytryptamine receptor 3A

BE0000311

HTR3A

antagonist

Specific functionexcitatory extracellular ligand-gated monoatomic ion channel activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons

Sodium-dependent dopamine transporter

BE0000647

SLC6A3

inhibitor

Specific functionamine binding

Cellular location

Cell membrane

General function & pharmacology

Mediates sodium- and chloride-dependent transport of dopamine .
PMID:10375632 PMID:11093780 PMID:1406597 PMID:15505207 PMID:19478460 PMID:39112701 PMID:39112703 PMID:39112705 PMID:8302271

Also mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline) (By similarity). Regulator of light-dependent retinal hyaloid vessel regression, downstream of OPN5 signaling (By similarity)

Neuronal acetylcholine receptor subunit alpha-2

BE0000738

CHRNA2

antagonist

Specific functionacetylcholine receptor activity

Cellular location

Synaptic cell membrane

General function & pharmacology

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators .
PMID:18723036
CHRNA2 forms heteropentameric neuronal acetylcholine receptors with CHRNB2 and CHRNB4 and plays a role in nicotine dependence PMID:24467848 PMID:27493220

Metabolizing enzymes(1)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

BCHECholinesterase

substrate

inhibitor

Transporters(3)

Proteins that transport this drug across cell membranes

Sodium-dependent dopamine transporter

BE0000647

SLC6A3

inhibitor

Specific functionamine binding

Cellular location

Cell membrane

General function & pharmacology

Sodium-dependent noradrenaline transporter

BE0000486

SLC6A2

inhibitor

Specific functionactin binding

Cellular location

Cell membrane

General function & pharmacology

Mediates sodium- and chloride-dependent transport of norepinephrine (also known as noradrenaline), the primary signaling neurotransmitter in the autonomic sympathetic nervous system .
PMID:2008212 PMID:8125921 PMID:38750358

Is responsible for norepinephrine re-uptake and clearance from the synaptic cleft, thus playing a crucial role in norepinephrine inactivation and homeostasis (By similarity). Can also mediate sodium- and chloride-dependent transport of dopamine PMID:11093780 PMID:8125921 PMID:39395208 PMID:39048818

Sodium-dependent serotonin transporter

BE0000749

SLC6A4

inhibitor

Specific functionactin filament binding

Cellular location

Cell membrane

General function & pharmacology

Serotonin transporter that cotransports serotonin with one Na(+) ion in exchange for one K(+) ion and possibly one proton in an overall electroneutral transport cycle. Transports serotonin across the plasma membrane from the extracellular compartment to the cytosol thus limiting serotonin intercellular signaling .
PMID:10407194 PMID:12869649 PMID:21730057 PMID:27049939 PMID:27756841 PMID:34851672

Essential for serotonin homeostasis in the central nervous system. In the developing somatosensory cortex, acts in glutamatergic neurons to control serotonin uptake and its trophic functions accounting for proper spatial organization of cortical neurons and elaboration of sensory circuits.

In the mature cortex, acts primarily in brainstem raphe neurons to mediate serotonin uptake from the synaptic cleft back into the pre-synaptic terminal thus terminating serotonin signaling at the synapse (By similarity). Modulates mucosal serotonin levels in the gastrointestinal tract through uptake and clearance of serotonin in enterocytes. Required for enteric neurogenesis and gastrointestinal reflexes (By similarity).

Regulates blood serotonin levels by ensuring rapid high affinity uptake of serotonin from plasma to platelets, where it is further stored in dense granules via vesicular monoamine transporters and then released upon stimulation .
PMID:17506858 PMID:18317590
Mechanistically, the transport cycle starts with an outward-open conformation having Na1(+) and Cl(-) sites occupied. The binding of a second extracellular Na2(+) ion and serotonin substrate leads to structural changes to outward-occluded to inward-occluded to inward-open, where the Na2(+) ion and serotonin are released into the cytosol. Binding of intracellular K(+) ion induces conformational transitions to inward-occluded to outward-open and completes the cycle by releasing K(+) possibly together with a proton bound to Asp-98 into the extracellular compartment.

Na1(+) and Cl(-) ions remain bound throughout the transport cycle .
PMID:10407194 PMID:12869649 PMID:21730057 PMID:27049939 PMID:27756841 PMID:34851672

Additionally, displays serotonin-induced channel-like conductance for monovalent cations, mainly Na(+) ions. The channel activity is uncoupled from the transport cycle and may contribute to the membrane resting potential or excitability (By similarity)

Biological pathways(1)

Procaine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Potassium cation,Procaine

Scientific references(1)

Gentry C.L., Lukas R.J.

Local Anesthetics Noncompetitively Inhibit Function of Four Distinct Nicotinic Acetylcholine Receptor Subtypes.

The Journal of Pharmacology and Experimental Therapeutics

2001299(3):1038-1048. doi: 10.1016/s0022-3565(24)29227-2

PMID: 11714893 DOI: 10.1016/s0022-3565(24)29227-2

ATC classification(4 codes)

ATC N01BA52

ATC C05AD05

ATC S01HA05

ATC N01BA02

Affected organisms(1)

Humans and other mammals

Salt forms(3)

Procaine hydrochloride(DBSALT000551)

Procaine nitrate(DBSALT002216)

Procaine phosphate(DBSALT002215)

Experimental properties(5)

External resources(1)

Drugs.com

Commercial products(7)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Procaine

DB00721

CAS number

59-46-1

UNII (FDA)

4Z8Y51M438

InChI Key (molecular fingerprint)

MFDFERRIHVXMIY-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

8836

ChEBI

8430

PubChem Compound

4914

PubChem Substance

46507724

KEGG Compound

C07375

KEGG Drug

D08422

ChemSpider

4745

BindingDB

64452

PharmGKB

PA451110

Therapeutic Targets Database

DAP000296

IUPHAR

4291

Guide to Pharmacology

4291

Wikipedia

Procaine

ChEMBL

CHEMBL569

ZINC

ZINC000001530757

RxCUI

8701

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10582

GenAtlas

SCN10A

GeneCards

SCN10A

GenBank Gene Database

AF117907

GenBank Protein Database

4838145

IUPHAR

585

Guide to Pharmacology

585

UniProtKB

Q9Y5Y9

UniProt Accession

SCNAA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:16767

GenAtlas

GRIN3A

GeneCards

GRIN3A

GenBank Gene Database

AJ416950

GenBank Protein Database

20372905

IUPHAR

460

UniProtKB

Q8TCU5

UniProt Accession

NMD3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5297

GenAtlas

HTR3A

GeneCards

HTR3A

GenBank Gene Database

D49394

GenBank Protein Database

681914

IUPHAR

373

Guide to Pharmacology

373

UniProtKB

P46098

UniProt Accession

5HT3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11049

GenAtlas

SLC6A3

GeneCards

SLC6A3

GenBank Gene Database

M96670

GenBank Protein Database

553260

Guide to Pharmacology

927

UniProtKB

Q01959

UniProt Accession

SC6A3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1956

GenAtlas

CHRNA2

GeneCards

CHRNA2

GenBank Gene Database

U62431

GenBank Protein Database

1458110

IUPHAR

463

Guide to Pharmacology

463

UniProtKB

Q15822

UniProt Accession

ACHA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6284

GenAtlas

KCNMA1

GeneCards

KCNMA1

GenBank Gene Database

U13913

GenBank Protein Database

537439

IUPHAR

380

Guide to Pharmacology

380

UniProtKB

Q12791

UniProt Accession

KCMA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6285

GeneCards

KCNMB1

GenBank Gene Database

U25138

GenBank Protein Database

1326067

UniProtKB

Q16558

UniProt Accession

KCMB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6286

GenAtlas

KCNMB2

GeneCards

KCNMB2

GenBank Gene Database

AF099137

UniProtKB

Q9Y691

UniProt Accession

KCMB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6287

GeneCards

KCNMB3

GenBank Gene Database

AF139471

GenBank Protein Database

5880671

UniProtKB

Q9NPA1

UniProt Accession

KCMB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6289

GeneCards

KCNMB4

GenBank Gene Database

AF160967

GenBank Protein Database

7799988

UniProtKB

Q86W47

UniProt Accession

KCMB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6293

GenAtlas

KCNN4

GeneCards

KCNN4

GenBank Gene Database

AF000972

GenBank Protein Database

2584866

IUPHAR

384

Guide to Pharmacology

384

UniProtKB

O15554

UniProt Accession

KCNN4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6290

GeneCards

KCNN1

GenBank Gene Database

U69883

GenBank Protein Database

1575661

Guide to Pharmacology

381

UniProtKB

Q92952

UniProt Accession

KCNN1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6291

GeneCards

KCNN2

GenBank Gene Database

AF239613

GenBank Protein Database

10334701

Guide to Pharmacology

382

UniProtKB

Q9H2S1

UniProt Accession

KCNN2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6292

GeneCards

KCNN3

GenBank Gene Database

AF031815

GenBank Protein Database

3309531

Guide to Pharmacology

383

UniProtKB

Q9UGI6

UniProt Accession

KCNN3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:9035

GenAtlas

PLA2G4A

GeneCards

PLA2G4A

GenBank Gene Database

M72393

GenBank Protein Database

190007

Guide to Pharmacology

1424

UniProtKB

P47712

UniProt Accession

PA24A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:20123

GeneCards

ASPG

UniProtKB

Q86U10

UniProt Accession

LPP60_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2976

GenAtlas

DNMT1

GeneCards

DNMT1

GenBank Gene Database

X63692

GenBank Protein Database

1632819

Guide to Pharmacology

2605

UniProtKB

P26358

UniProt Accession

DNMT1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2978

GeneCards

DNMT3A

UniProtKB

Q9Y6K1

UniProt Accession

DNM3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:983

GenAtlas

BCHE

GeneCards

BCHE

GenBank Gene Database

M32391

GenBank Protein Database

1311630

Guide to Pharmacology

2471

UniProtKB

P06276

UniProt Accession

CHLE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11049

GenAtlas

SLC6A3

GeneCards

SLC6A3

GenBank Gene Database

M96670

GenBank Protein Database

553260

Guide to Pharmacology

927

UniProtKB

Q01959

UniProt Accession

SC6A3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11048

GenAtlas

SLC6A2

GeneCards

SLC6A2

GenBank Gene Database

M65105

GenBank Protein Database

189258

Guide to Pharmacology

926

UniProtKB

P23975

UniProt Accession

SC6A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11050

GenAtlas

SLC6A4

GeneCards

SLC6A4

GenBank Gene Database

X70697

GenBank Protein Database

36433

Guide to Pharmacology

928

UniProtKB

P31645

UniProt Accession

SC6A4_HUMAN

International reference pricing

10 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.15/ml

To $2.40/ml

Procaine hcl 2% vial

$0.15/ml

Chloroprocaine 2% vial

$0.26/ml

Chloroprocaine 3% vial

$0.33/ml

Nesacaine 1% vial

$0.72/ml

Nesacaine 2% vial

$0.74/ml

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Procaine hydrochloride 40mg/2ml solution for injection ampoules

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

NICE clinical guidance(3)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
16

Chemical identifiers

Procaine

Additional database identifiers

International reference pricing

DrugBank citations

Procaine hydrochloride 40mg/2ml solution for injection ampoules

Safety & regulatory

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(3)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Half-life

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science16

Chemical identifiers

Procaine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
16